Philip Morris
Health and Safety Risk Analyses: Information for Better Decisions
Fields
- Author
- Lave, L.B.
- Area
- LOGUE,MAYADA/OFFICE
- Type
- MAGA, MAGAZINE ARTICLE
- BIBL, BIBLIOGRAPHY
- Site
- N426
- Request
- Stmn/R1-072
- Named Organization
- Congress
- Epa, Environmental Protection Agency
- FDA, Food and Drug Administration
- Epa, Environmental Protection Agency
- Named Person
- Byrd, D.
- Delaney
- Hutt, P.
- Lave, J.
- Lave, T.
- North, W.
- Slovic, P.
- Whipple, C.
- Delaney
- Document File
- 2025545619/2025546382/Harvard University Office of
- Continuing Education Short Course Program Harvard School
- of Public Health
- Continuing Education Short Course Program Harvard School
- Litigation
- Stmn/Produced
- Author (Organization)
- Carnegie Mellon Univ Pittsburgh
- Science
- Master ID
- 2025545673/6381
Related Documents:- 2025545673-6381 Risk Analysis in Occupational and Environmental Health 910904 - 910906
- 2025545684 Telephone Locations and Protocol
- 2025545689-5696 Risk Assessment for Carcinogens: A Comparison of Approaches of the Acgih and the Epa
- 2025545697 Hps Newsletter Interview with A Risk Expert
- 2025545698-5711 Science and Its Limits: the Regulator's Dilemma
- 2025545713-5721 Risk / Benefit Analysis
- 2025545722-5725 Risk Management Commentary for Dr. D. Allan Bromley Assistant to the President for Science and Technology
- 2025545726-5729 Risk Assessment and Comparisons: An Introduction
- 2025545750-5792 Risk Assessment of Chemical Carcinogens: Is It Time for A Change?
- 2025545795-5799 Tools of Risk Analysis Applications of Epidemiology
- 2025545800-5810 Notice of Intended Changes - Benzene
- 2025545811-5822 Epidemiology in Risk Assessment for Regulatory Policy
- 2025545824-5850 Risk Analysis in Environmental and Occupational Health Use of Animal and Other Data As Predictors of Human Risk
- 2025545851-5871 Risk Analysis in Environmental and Occupational Health Uncertainties in Predicting Human Risks
- 2025545872-5881 How Do Cancer Risks Predicted From Animal Bioassays Compare with the Epidemiologic Evidence? the Case of Ethylene Dibromide
- 2025545882-5887 Use of Biological Assays in Short-Term Assessment of Inhaled Substances
- 2025545888
- 2025545889-5891 Risk Analysis in Environmental and Occupational Health Are Your Mushrooms Safe to Eat?
- 2025545892-5899 the Rat As An Experimental Animal
- 2025545901-5907 Non-Cancer Endpoints
- 2025545910-5939 Cancer Facts & Figures - 890000
- 2025545940-5941 Cancer Facts & Figures - 890000
- 2025545942-5944 Get - the - Lead - Out Guru Challenged A Decade-Old Scientific Argument Over the Effects of Low-Level Lead on Iq Turns Nasty Following Allegations of Misconduct
- 2025545945-5948
- 2025545949-5958 the Question of Thresholds for Radiation and Chemical Carcinogenesis
- 2025545959-5980 Are There Thresholds for Carcinogenesis? the Thorny Problem of Low-Level Exposure
- 2025545981-5990 Perspectives on Comparing Risks of Environmental Carcinogens
- 2025545991-5998 Acceptable Cancer Risks: Probabilities and Beyond
- 2025546000-6011 Ideas in Pathology Pivotal Role of Increased Cell Proliferation in Human Carcinogenesis
- 2025546012-6017 Cell Proliferation in Carcinogenesis
- 2025546019-6027 the Role of Expert Judgement in Risk Analysis
- 2025546029-6039 the Respiratory Tract As A Route of Exposure
- 2025546040-6045 the Respiratory Tract As A Portal of Entry for Toxic Particles
- 2025546047-6062 Limitations to the Use of Employee Exposure Data on Air Contaminants in Epidemiologic Studies
- 2025546063-6083 Benefit - Cost Analysis of Environmental Regulation: Case Studies of Hazardous Air Pollutants
- 2025546086-6089 Legislative and Regulatory Aspects of Risk
- 2025546090-6099 Connecticut's Dioxin Ambient Air Quality Standard
- 2025546100-6103
- 2025546105 Annals of Radiation Calamity on Meadow Street
- 2025546106 Caution Urged When Using Insect Repellents
- 2025546116 Volatile Organics and Inorganics Action Levels 900400
- 2025546134-6135 Summary of Radon Test Results of the Household Testing Program
- 2025546141-6145 Introduction to Discussion Sessions
- 2025546146-6149 Risk Assessment in Environmental and Occupational Health Risk of Alar (Daminozide)
- 2025546150-6160 Intolerable Risk: Pesticides in Our Children's Food
- 2025546161-6162 Pesticides, Risk, and Applesauce
- 2025546163-6168 Daminozide Special Review Technical Support Document - Preliminary Determination to Cancel the Food Uses of Daminozide
- 2025546169 Daminozide / Udmh
- 2025546170-6172 the Relative Risk of Daminozide (Alar / Kylar) Use
- 2025546173 Be Most Wary of Nature's Own Pesticides
- 2025546174-6175 A Movie Star Pares the Apple Industry
- 2025546176-6183 Summary of Toxicology Data on Daminozide and Udmh
- 2025546184-6194 Attachment I Graphs of Data From NCI / Ntp 83 Daminozide
- 2025546195-6196
- 2025546197-6202 Daminozide Special Review Technical Support Document - Preliminary Determination to Cancel the Food Uses of Daminozide
- 2025546203-6224 Regulatory Decision - Making Under Uncertainty: the Case of Alar
- 2025546226 Epa Moves to Reassess the Risk of Dioxin Urged on by the Scientific Community, Epa Is Developing A New Model for Estimating Dioxin's Risk
- 2025546227 US Government Orders New Look at Dioxin the Environmental Protection Agency Is Evaluating Data From the Past Decade That Suggest Dioxin's Toxicity May Be Overestimated. A Risk Assessment Model Based on Biological Mechanism Is Being Drawn Up.
- 2025546228-6235 Dioxin Toxicity: New Studies Prompt Debate, Regulatory Action New Data on Dioxin's Effect on Humans, A Clearer Picture of the Cellular Events It Precipitates, and New Animal Toxicity Studies May Provide Epa with A Firm Basis for Regulation
- 2025546236-6250 the Regulation of Gene Expression by 2,3,7, 8-Tetrachlorodibenzo-P-Dioxin
- 2025546251-6253 Dioxin Risks Revisited Armed with A New Understanding of How Dioxin Works on the Molecular Level, A Number of Scientists Are Challenging Epa to Change the Way It Does Risk Assessment
- 2025546255-6258 Lead Toxicity Case Study for Short Course on Risk Analysis in Occupational and Environmental Health 910904 - 910906
- 2025546259-6267 Lead
- 2025546268-6275 Lead in Bone: Implications for Toxicology During Pregnancy and Lactation
- 2025546276-6281 the Long-Term Effects of Exposure to Low Doses of Lead in Childhood An 11 - Year Follow-Up Report
- 2025546282-6285
- 2025546298-6321 Review 890000 Alice Hamilton Lecture Lead and Human Health:Background and Recent Findings
- 2025546323-6348 Traps and Errors in Risk Analysis
- 2025546349-6356 Health Risks the Perception of Reality and the Realty of Perception
- 2025546357-6362 Communicating Risk Under Title III of Sara: Strategies for Explaining Very Small Risks in A Community Context
- 2025546363-6368 Industrial Risk Perceptions
- 2025546369-6370 Too Many Rodent Carcinogens: Mitogenesis Increases Mutagenesis
- 2025546371-6373 Has Risk Assessment Become Too 'conservative'?
- 2025546379-6381 Telling Reporters About Risk Dealing with Reporters Needn't Be the Least Agreeable Part of the Job.
- Characteristic
- EXTR, EXTRA
- Date Loaded
- 24 May 1999
- UCSF Legacy ID
- rmp02a00
Document Images
~-Iealth and Safety Risk Analyses:
IniFormation for Better Decisions
LESTER B. LAvE
Knowing the nature and magnitude of health and safety
risks is helpful in setting priorities as well as in making
decisions about pursuing recreational activities, foods,
jobs, and other aspects of everyday living. `°Risk-risk"
situations xequire a choice among risky alternatives.
"How saf -.Y" situations involve a more general choice as to
how much of other desired activities to sacrifice for
increased safety. "How safe" situations are inherently
more diffictdt to manage, because they are subject to fuzzy
thinking and rhetoric. The large uncertainties of current
estimates must be conveyed explicitly to arrive at sensible
decisions.
W HAT WOULD YOU DO, IDI TI3E FOLLOWING STTUATTODIS:
(i) You have a partially blocked coronary artery that can
be treated by bypass surgery or medication. Although
there is a chance of dying during surgery, if you survive you can
expect less pain and a more active life than from medication. (ii)
Your neighbarhood school contains asbestos materials. School
officials can ignore the problem or pay for the removal of the
asbestos with Cunds from educational programs or a special property
tax.
These two situations exemplify the types of health and safery
hazards that -,ll of us face (1). Intelligent decisions are needed on
which potential hazards to ignore and how much risk reduction to
seek. These decisions require information about the nature and
probability of the hazard, how the risk is perceived, and safety goals.
The available data and tools to provide this information are
replete with wZcertainty, which complicates the decision process and
occasionally negates the value of an analysis. The hard choices are
clothed in uncertainty and conflicting goals. People feel deeply
about health and safety issues but become uncomfortable when
thinking about situations that involve danger to their children or to
themselves.
The corona y heart disease situation has risks and benefits associ-
ated with bxh choices. With such "risk-risk" situations, a person
must select the better alternative (2). For the asbestos situation, the
probabilit,v of cancer can be lowered, but only by giving up other
desired servioes or activities. In such "how safe is safe enough"
situations, sxiery must decide how much should be sacrificed to
reduce risk. :E<<ch successive reduction in risk generally achieves a bit
less and costs a little more, such as when reducing the levels of trace
carcinogens in drinking water (3).
Despite the inevitable uncertainties, risk analysis has much to
contribute to risk management. Risk analysis helps identify signifi-
cant hazards, stimulates basic research, and spotlights the need to
agree on health goals and priorities. In the past decade risk
quantification has challenged much of the conventional wisdom
about the safety of our technologies and the efficacy of particular
interventions.
Risk Analysis in Medical Decision-Making
Progress in science enhances understanding of the possible
sources of harm and allows quantification of the probabilities, at
least crudely. For example, one to two patients out of 100 die during
bypass surgery (4). This datum simplifies the "risk-risk" situation for
many people who would regard this probability as small in compari-
son with other dangers in this situation. But some individuals are at
extraordinary risk. The tabulated frequency of deaths is the accumu-
lated experience from many surgeons, hospitals, and patients of
diverse characteristics. The chance of death during surgery would be
much less for a 40-year-old in good physical condition with no other
medical pr.oblems than for an 80-year-old with severe deterioration
of the heart muscle and an inexperienced surgeon.
An individual's perception of the value of outcomes and desire for
certainty are important detemlillants in the decision (5). A sports
enthusiast might regard medical treatment of coronary heart disease
as useless. Someone afraid of "dying on the table" might elect
medical treatment instead of surgery. A patient without insurance
would see the large costs associated with surgery. Even the way the
outcomes are described, whether in terms of probabiliry of dying or
probability of survival, is likely to affect the choice of treatment (6).
There is no single optimal decision for all people.
The key issues in medical decision-making are the extent and
quality of information about the outcomes of alternative interven-
tions, the incentives influencing the ill person and those treating
him, and the preferences of those involved (7). Occasionally,
decisions are as simple as treating a broken bone: information is
good, treatment is beneficial and carries few complications, and
there is a dominant decision. More generally, getting the right
information is difficult or impossible. For example, a specialist in
one mode of treatment finds it difficult to be neutral in offering
advice because of his confidence in his skill and approach, his
unfamiliarity with other approaches, and the financial incentive.
Even the best available data bristle with snares. For example,
cigarette smoking is the most important public health issue. Yet
there is no confident answer to individuals who ask about their risk
from smoking. Even a more-than-two-pack-a-day smoker has only a
15.6% chance of dying of a smoking-related disease before age 65
(36.4% before age 85); thus, some individuals, for genetic or other
_ reasons, arc more susceptible than others (8).
The author is 'faines Higgins Professor of Economics, Carnegie-Mellon University,
Pitsburgh, PA 1,,213.
Risk analysis has enlightened decision-making in two ways. First
it has allowed quantification of the chances of adverse outcomes
17 APRIL 1987 ARTICLES 291

more preciscly as well as of the quality of life and life expectancy
implications of alternative modes of treatment. Second, it promotes
the evaluation of treatment modes and individual performers. Many
treatment modes have been found to be without efficacy, for
example, routine removal of tonsils or radical mastectomies (7);
some hospitals or surgeons have relatively poor outcomes, such as
surgeons doing only a few coronary bypass operations each year (4).
Risk estimatis are even more important in evaluating screening
and preventive care, since individuals are counselled to seek these
services (9). For this counsel to be ethical, not only must the action
not be harmful., it must have a reasonable chance of benefiting the
person. For cxalnple, on average 7.58% of U.S. women contract
breast cancer. Early detection (through screening by physical exami-
nation plus x-ray) and treatment was found to decrease breast cancer
mortality 40°,6 (10). However, the screening is not an unalloyed.
benefit since a single marnmogram in a 35-year-old woman involv-
ing a dose of 1 rad would increase the chance of cancer to between
7.59 and 7.61%. For annual examinations, the chance of cancer
would rise to between 7.90 and 8.25%. Thus, mammography can
have an apprecxable risk. Screening at an earlier age or more
examinations would increase the chance of radiogenic cancer, while
offering dimilushing incremental benefit in detecting disease. Al-
though modem equipment has reduced the dose per plate about 50-
fold, a screening protocol must balance the hazards of screening
against those of undetected disease, considering the risk factors for
each group.
Some modern equipment is designed to use more than twice as
many x-rays per examination as in the clinical trial that showed
efficacy. A Pittsburgh physician reports that in more than half the
baseline examinttions, radiologists recommend retesting because of
some suspicious aspect of the film (11). The quest for greater
certainty appears to have led some radiologists to increase the chance
of inducing cancer, with presumably little improvement in detec-
tion. While the increased sensitivity of the equipment has lowered
the dose per plar.e significantly, there is still a need to be concerned
about inducin;g radiogenic cancer. Some radiologists appear to be
making a decision about,how much uncertainty to tolerate without
calculating the benefits and risks of the extra plates and follow-up
test. A risk-ben.efit calculation is needed and plates should be
eliminated when. they do not change treatment or are done only to
avoid malpraaice suits. A similar quesdon occurs, although in less
dramatic form, when physicians order additional tests that do not
have health tlueiits but do increase costs. How much should society
be willing to pay to reduce risk?
Quantification of Risk
The dangers of being in a building with undamaged asbestos
materials can b- quantified for the "how safe" situation. The
probability of ddldren getting mesothelioma or lung cancer from
such asbestos exposure in school is estimated to be about five per
million lifetimes, less than 1/5000 the chance of death faced by these
children from otiaer current events in their lives (12). This analysis
leads some to ne,glect asbestos in order to concentrate on reducing
other risks, suclt as reducing time spent in the same room as
cigarette smoken;, wearing seat belts, or improving the quality of
children's education and personal consumption. Others regard this
additional risk from asbestos as nontrivial and want it removed.
Careless removal of asbestos, however, can pose major risks to the
workmen as well as to the children; many experts believe that
asbestos in good repair ought to be left in place and removed only
when there is a major renovation or a building is demolished (13).
At the current state of knowledge, quantifving risk is somewhat
arbitrary. The estimated probabilities have large margins of uncer-
tainty and are calculated from populations that may be quite unlike
the individual having to make a decision. It is not a comfort to know
that, on average, exposure to arsenic, chromium, or coke oven gases
is not a major source of cancer in the United States if you live just
downwind of a major emissions source (14).
The best probability estimates would come from a"perfett"
(controlling for confounding factors) epidemiology study on the
population of interest at the range of doses or exposures of interest.
There are no such studies, however, and, for most hazards, no
human data at all. Epidemiology studies always have one or more of
the following problems: too few subjects for confident conclusions,
failure to control for important confounding factors, no data (or
little data) on exposure, exposure levels many times greater than the
standards being considered, inadequate diagnosis, subjects lost to
follow-up, or subjects who are qualitatively different from the
population to be protected The Environmental Protection Agency
(EPA) classifies epidemiology studies as sufficient, limited, or
inadequate and then disregards the inadequate studies (15). Since
experimental manipulation is not possible, a hard-nosed critic would
regard every study as inadequate. Rather, scientists have to ask what
can be learned from each study and the studies taken together, and
how much confidence can be placed in the results (16).
Often, probabilities must be estimated from laboratory studies.
Extrapolation of data from rodents or cultured cells to people is
fraught with difficulties (17, 18). Since humans do not have zvmbal
glands, how should one interpret a study finding that a chemical
causes cancer in the zt rnbal gland of rats? Until science is able to
clarify the implications of such findings, regulators usually make the
most conservative (that is, worst case), plausible assumption in each
situation-for example, any chemical that increases the number of
tumors (benign or malignant) in rodents (even in the zymbal gland)
is assumed to be carcinogenic in people. The hope is that improve-
ment in scientific understanding will obviate the need for arbitrary
assumptions. Initial data on pharmacokinetics and DNA adducts are
beginning to clarify critical issues (19). To date regulatory agencies
seem reluctant to use these data when they imply lower estimated
risks. But regulators must remember that current practice is based
on assumptions rather than data; insisting that the current, some-
what arbitrary, assumptions cannot be changed until there is
sdentific consensus on a new approach' is to choose assumptions
based on little or no data over models validated by data.
In estimating probabilities from either human or rodent data, the
standard assumption is that incidence is proportional to dose
measured in milligrams per kilogram of body weight or body surface
area (a linear, no threshold dose-response relation), a conservative
assumption but still one that is plausible in some cases. Data from
both epidemiology and rodent studies show that linearity is the best
assumption over a wide range for carcinogens such as ionizing
radiation (20). For some carcinogens, halving the dose reduces the
number of tumors by less than half whereas for most chemicals
tested, halving a large dose more than halves the number of tumors.
The extreme case occurs for carcinogens that are essential nutrients.
Level'S of chromium and nickel essential for nutrition are estimated
to cause a small number of cancers (21).
Finally, current practice for EPA in carcinogen assessment is not
to use the best (maximum likelihood or central tendency) estimate
of the linear term coefficient in a multistage model. Rather, they
construct a 95% confidence interval about that estimated coefficient
and use the upper bound (22).
Although conservative assumptions are the rule, there are several
places where the risk estimates might understate the true risk. First,
people are not exposed to a single chemical, but rather to a number
of chemicals. Even if they act independently, the risk will be the sum
292 SCIENCE, VOL. 236

of individua;': chemical risks. Second, the chemicals may interact and
potendate or dampen the effects of other chemicals. Third, some
individuals may be pardcularly sensitive to some chemicals, more so
than the rodents used in testing.
Nonetheless, agency risk assessors believe that, in general, their
risk estimates overstate the true risks. In many cases there may be no
risk to hum,,m associated with current exposure levels. While ther
is still some chance that the risk estimates may understate true risks,
agencies fi;ICI that there is little threat associated with many environ-
mental situations that cause popular concern, such as asbestos in
good repair in buildings (12, 14, 23, 24). In contrast, the estimated
risk associao.d with some hazards, such as radon in buildings, is
extremely li,gh for some homes (as high as 10,000 per millior
lifetimes), arsenic emissions from smelters (as high as 360,000 pei
million lifetimes), and some food contaminants (the tolerance levei
for aflatoxin in corn implies 700 cancers per million lifetimes) (14).
Current leve;ls of public concern are not closely aligned to the
estimated risk level (25).
The value and even the interpretation of risk estimates are
compromised by arbitrary assumptions, some conservative and some
that would understate the true risk. Arbitrary assumptions inject
scientists' personal goals or interpretations of public desires into the
risk analysis. Rather, the risk analysis should reflect the best science,
the range of plausible models, and judgments, based on the best
science, of the appropriate confidence intervals about these esti-
mates. The risk managers need unbiased information with the
uncertainties displayed explicitly to help them arrive at good
decisions. BUgulatory agencies should arrive at similar risk estimates
for a substance. The, risk management decisions may differ across
agencies, depending on the goals embodied in the statutes and the
individual costs and benefits of control.
Food Additives
Food addi.rives can introduce hazards and tend to elicit a great
deal of emotional response (26). "Risk-risk" situations occur, as
when sodiimi nitrite increases the chance of cancer but reduces the
chance of botulism. More frequent are "how safe" situations, where
food additiv s improve the flavor, appearance, or shelf life of food
but also increase the chance of cancer. Is having brightly colored
maraschino cherries worth even a minuscule threat (the risk of red
food color is estimated to be 0.02 cancer per million lifetimes)
(14)?
Consumers do not "need" nonnutritive sweeteners, color addi-
tives, or antioxidizers; food can be less sweet, can be sweetened with
sugar, need not have vibrant colors, and can be susceptible to
spoiling more quickly. To some people, these properties are of little
value; when foods are properly labeled, they select food without
additives. To others, these properties are important and worth a tiny
increase in the chance of cancer. As long as people understand the
hazards, they can make their own choices. For saccharin-sweetened
foods, Congress has required that the label must indicate ingredients
and that warning signs be posted informing people of the carcino-
genic potenti al.
The mandite of the Food and Drug Administration (FDA) is to
prevent food from becoming contaminated or adulterated; the FDA
is to ensure that the, food supply is healthy (and varied and not
needlessly expensive) (26). That mandate requires that the FDA
define standards for what is aesthetically acceptable and what is safe
enough. The FDA has evolved a policy that if a food additive (or its
metabolites or breakdown products) increases the chance by less
than one cancers per million lifetimes, the threat is considered to be
too small to be of concern (27). This policy is highly controversial
17 APRIL 158;'
and the subject of litigation. However, given the natural toxic
substances in food, it is unclear what a sensible alternative would be
(28). The FDA finds the upper bound cancer probabilities for some
food constituents and contaminants to be much larger than the
comparable figure for food additives (one cancer per million
lifetimes or less). For example, the tolerance level of aflatoxin in cor
is estimated to increase the incidence of cancer by as much as 70,
per million lifetimes (14).
What is the meaning of an estimated probability such as one
cancer per million lifetimes (29)? The actual chance might well be
zero, since a rodent carcinogen might not be a human carcinogen, or
it might be larger, because humans are more sensitive to this
chemical than rodents. Applied to the United States, this estimate
literally means 230 cancers over 70 years or 3 to 4 additional cancers
each year, added to the 1 million "background" cancers. In particu-
lar, food colors, such as those used in coloring fruit cocktail, increase
the risk about 0.4 cancer per million lifetimes, or about one cancer
each year for the U.S. population.
As long as people are presumed to be reasonably well informed
and to be capable of making their own judgments, those who like
vibrant colored fruit cocktail can consume it while others can avoid
it. However, if this food is consumed by someone ignorant of the
risks, such as a child, societ,v must decide whether the food colors
should be banned. Apparently, the FDA considers a risk estimate of
one cancer per million lifetimes to be small enough to let individuals
make their own decisions, even if there are some people who take
the risk without realizing it.
Traumatic Injuries and Death
Risk assessment has had a long history in analysis of "accidents."
In 1985, 92,500 Americans were killed (about 5% of all deaths) and
9 million persons sustained disabling injuries from accidents (30
Almost half the deaths (45,600) were highway-related, 11,600 wer,
work-related, 20,500 occurred at home, and 19,000 were other
public accidents. Almost 60 million people were injured, resulting in
543 million restricted activity days. Safety analysts dislike the term
"accident" since it has a connotation of being beyond human
control. Instead, each trauma injury has a cause, and steps could
have been taken to avoid it or at least mitigate the injury.
"Risk-risk" situations occur in designing safety equipment. If an
energy-absorbing steering column in an automobile is designed to
protect the driver during a low-speed crash, it offers less protection
in a high-speed crash, and vice versa. One "how safe" situation is the
controversy over whether air bags should be mandated in cars.
There is no doubt that air bags would save lives, but the cost per life
saved would be about S 1 million (31).
A variety of approaches have been used to assess the frequencies
and mitigation possibilities (32). The most important is statistical
analysis to identify the frequency of events and conditions leading to
injury or death. Others include crash investigation, injury epidemi-
ology, behavioral feedback, economic approaches, human factors,
and more recently, the use of fault and event trees (32). The last
approach is embodied in probabilistic risk analysis, developed for
nuclear reactors and now used in other areas (33).
Aside from an occasional enthusiastic speech, no one talks about
eliminating trauma-that would require banning activity. Activities
such as mountain climbing are chosen by adults who can be
presumed to be reasonably informed of the risks. For all activities,
society tries to decrease risk by encouraging safe behavior and safer
products; enhancing safety stops when the cost and inconvenien
of increased safery exceeds the benefit of the safety gains (a "ho-,.
safe" decision). The social decision is complicated by human
ARTICLES 293
2025546376

r
,
reactions to the safer product that could increase risk (34); when
people do not use safety features, their use can be mandated (35).
Injury rate:; have declined markedly over many decades, whether
measured by the fatalities per passenger mile for automobiles and
commercial a'Lrcraft or occupational injury rates (30). Most of this
decline is not related to governmental standards and inspection, but
rather seems to come from company and consumer decisions as
influenced by legal liability (36).
Risk Mam a.gement
Risk analysils is done to enlighten decisions about "how safe" and
"risk-risk" situations (37). Since the risk estimates have major
uncertainties, they may be useless to the risk manager. If a toxic
chemical is inexpensive to control or replace, even a hint of toxicity
might lead to control (38), such as occurred in the banning of
cydamate. If . chemical is difficult to replace, such as vinyl chloride
monomer or saccharin in 1978, it is unlikely to be banned even if the
number of deaths associated with its use is nontrivial (39).
Although the dose-response relation has received the most atten-
tion, for health risks, exposure assessment adds greater uncertainty.
This is anomalous since improving exposure assessment is not
difficult.
Providing warning labels and signs does not guarantee that
people will rea,d them or understand them (40). However, there is a
basic social choice about the extent to which individuals should be
allowed to rnake their own decisions and to be able to understand
the information provided and the consequences of their choices.
None of this means that the victim and others will not be terribly
sorry when a chance is taken and it turns out badly. What range of
hazardous choices will society allow to individuals (41)? What
information sl ould be available to inform these decisions? Society is
not and cannot be expected to maintain consistency, since these are
hard decisions. For example, society allows individuals to smoke
cigarettes wHe forbidding them to eat swordfish containing levels of
mercury that pDse a far lower risk. In some states a person traveling by
car to spend a day hang gliding must buckle his seat belt.
Some h=irds, such as those associated with a nuclear reactor or a
plant making pesticides, endanger people in the vicinity; the deci-
sion concerning where to locate them is inherently social in nature
since the indiv:iduals living nearby will have to accept this risk. Some
of these peoplee will see'the plant as offering a trivial increase in risk,
but others will see it as life threatening. Because individuals can do
little to adjust their risk level, these situations exasperate those who
disagree with the social decision (42).
"Risk-risk" situations require a balancing. This structure pre-
cludes rhetoric about being willing to spend anything to prevent a
premature death. The "how safe" situation invites fuzzy thinking
and rhetoric. The issue, is not how many pieces of green paper are
worth preventing a premature death, but rather how much inconve-
nience and discomfort to bear and how much consumption of other
goods and services to give up to lower the probability of disease or
death a bit more (43).
A person may appear to engage in inconsistent behavior in
smoking cigarettes while worrying about food additives or not
testing for radon while worrving about asbestos that is in good
repair. The apparent contradictions may result from a complicated
cognitive structure for perceiving hazardous situations (25). People
are concerned with aspects different from those that experts focus
on. Since they are the consumers and the voters in our democracy,
people are the final arbiters of how safe is safe enough.
For guidance on what risk levels to set, a variety of approaches has
been used. One attempts to find what is a trivial or de minimis risk,
294
so that the limited resources for improvement are not wasted to
reduce risks beyond this level (14, 44). A second approach is to
examine hazards that are readily accepted in everyday life and in
regulations (29). A third is to seek public guidance through
referendums or through the actions of elected representatives.
Several state referendums on nuclear power have done little to darify
public preferences; each was voted down but each was phrased in
such an extreme form that a moderate critic of nuclear power might
have voted against the measure. Congress has not been much more
informative, since legislation generally contains contradictory lan-
guage. For example, the Occupational Safety and Health Act sets a
goal" "... that no employee will suffer material impairment of
health or functional capacity ..."; however, the act also requires
that the regulations " . . . assure insofar as practicable . . ." which is
interpreted to mean both technical and economic feasibility. In one
of the few cases where Congress was unequivocal about setting a
stringent risk standard, the Delaney amendment to prohibit carcino-
genic food additives, the FDA has permitted them, as long as they
pose a tiny risk (17, 27). Congress, the agencies, and the courts are
concemed that safety regulations not be so stringent as to halt the
economy or even shut an industry. The result is that Occupational
Safety and Health Act and EPA sometimes tolerate extremely large
hazards because it is not technically or economically feasible to deal
with them.
Just as a great advantage of risk assessment is bringing the
calculations out into the open, uncertainties and all, so one of the
great advantages of risk management has been bringing the decision
process out into the open. Since the probabilities cannot be lowered
to zero, there is good reason to inform the affected parties and the
public of the basis for a decision. While it is time consuming and
apparently wasteful to reach these decisions in a fishbowl, there is no
other process likely to secure public confidence and consent.
Conclusion
Risk analysts should not attempt to overstate or understate
threats, but rather to give a best estimate and the range of
uncertainty. Decision-makers can choose the proper amount of
conservatism in setting the standard. The various federal agencies
ought to coordinate their risk assessment processes so that they will
arrive at similar estimates for a particular hazard.
Current risk estimates are fraught with uncertainry: Ttie process
of conducting and defending risk analyses highlights these uncer-
tainties and suggests a research agenda to resolve them. Rather than
reify existing arbitrary assumptions, the process must be opened to
new data and models, particularly since current assumptions often
are based on little or no data.
It is inherently easier to manage "risk-risk" situations than "how
safe" situations. The former are self-limiting and require an explicit
balancing of the risks. The latter are subject to rhetoric about zero
risk because there is no necessity to consider what is being sacrificed
to lower the probability further. Risk management is inherently
difficult not only because it requires setting specific goals, but
because the situations involved often affect many people simulta-
neously, requiring a collective decision. Since people have different
safety goals and are uncomfortable thinking about hazardous situa-
tions, collective decisions are difficult.
Progress in the field of risk analysis has been enormous-it hardly
existed a decade ago. The intellectual ferment comes from the focus
on helping to enlighten decisions, rather than on intellectual
elegance. The constant interaction of those involved in risk analysis
and in risk management is needed to stimulate analysts to make their
greatest contribution.
SCIENCE, VOL. 236

---
